Problem Management Plus (PM+) in Chile: a Pilot Randomized Controlled Trial of a Psychological Transdiagnostic Intervention Delivered in Primary Health Care
A Pilot, Single-blind, Randomized Controlled Trial Evaluating the Implementation Outcomes and Preliminary Efficacy of Problem Management Plus (PM+) Versus Treatment as Usual in Adult Primary Care Users With Symptoms of Depression and/or Anxiety
1 other identifier
interventional
56
1 country
1
Brief Summary
This study aims to evaluate the implementation outcomes of a pilot randomized controlled trial and to assess the preliminary efficacy of Problem Management Plus (PM+) in reducing symptoms of depression and anxiety among users at a Primary Health Care center in Chile. Two intervention groups will be compared: PM+ versus care as usual (CAU). The process will include an evaluation of the feasibility of the study procedures, as well as the acceptability and fidelity of the PM+ intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 24, 2025
CompletedStudy Start
First participant enrolled
May 9, 2025
CompletedFirst Posted
Study publicly available on registry
May 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 12, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 12, 2025
CompletedNovember 20, 2025
October 1, 2025
4 months
April 24, 2025
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Implementation outcome: Feasibility
Measured through components A and B. A. Percentage of participant recruitment: defined as the proportion of participants who consented to enroll in the trial and were subsequently recruited. B. Participant adherence to PM+: defined as the average number of PM+ sessions attended by each participant.
Feasibility outcome component A will be collected once recruitment is completed. Component B will be collected at week 6, starting from the first intervention week.
Implementation outcome: Acceptability
Indicators of PM+ acceptability among users and trained facilitators, assessed with quantitative scales. For users, an adapted version of the Abbreviated Acceptability Rating Profile (AARP) will be administered. The AARP consists of 8 Likert-scale items, yielding total scores ranging from 8 to 48, with higher scores indicating greater acceptability. For facilitators, an adapted version of the Acceptability of Intervention Measure (AIM) will be used. The AIM comprises 5 Likert-scale items, producing scores ranging from 4 to 20, where higher scores reflect greater acceptability. For both measures, descriptive statistics will be reported using median and interquartile range (IQR), as well as mean and standard deviation (x̄ \[SD\]).
Acceptability outcomes will be collected during the post-intervention assessment at week 6, starting from the first intervention week.
Implementation Outcome: Fidelity
Indicators of PM+ fidelity will be assessed with a study-specific rubric developed based on expert judgement. The rubric consists of 5 items, each reflecting a component of proper PM+ delivery. Items range from 1 ("low fidelity") to 4 ("high fidelity"), with higher scores indicating greater fidelity. The reported statistics will include the median and interquartile range (IQR) for each item, and the mean and standard deviation (x̄ \[SD\]) for the overall fidelity score per assessed PM+ session.
Fidelity outcomes will be collected throughout the intervention period, from the first to the final intervention week (week 5).
Secondary Outcomes (3)
Preliminary pre-to-post effect of PM+ on depressive symptoms.
Measured through baseline at week 0 and post-intervention assessment at week 6, starting from the first intervention week.
Preliminary pre-to-post effect of PM+ on anxiety symptoms.
Measured through baseline at week 0 and post-intervention assessment at week 6, starting from the first intervention week.
Preliminary pre-to-post effect of PM+ on self-identified problems.
Measured through baseline at week 0 and post-intervention assessment at week 6, starting from the first intervention week.
Study Arms (2)
Problem Management Plus (PM+)
EXPERIMENTALPM+ is delivered in five individual sessions conducted by trained healthcare professionals without previous expertise in mental health care.
Care as Usual (CAU)
NO INTERVENTIONCare as usual comprises the mental health services currently provided to Primary Health Care users in Chile.
Interventions
Problem Management Plus (PM+) will be delivered according to the Spanish version of the WHO protocol (OMS, 2016). PM+ is a low-intensity, transdiagnostic psychological intervention based on Cognitive Behavioral Therapy (CBT). The protocol incorporates evidence-based strategies, including problem-solving, stress management, behavioral activation, and accessing social support. The intervention consists of five individual 90-minute sessions provided by healthcare professionals without previous expertise in mental health care (WHO, 2018). PM+ helpers will be supervised by master trainers specifically trained for Chile. Two systematic reviews have demonstrated the effectiveness of PM+ in reducing symptoms of common mental disorders, such as depression and anxiety (Schäfer et al., 2023) and specific symptoms of post-traumatic stress (Akhtar et al., 2022).
Eligibility Criteria
You may qualify if:
- Individuals over 18 years old.
- Diagnosed with or presenting depressive and/or anxiety symptoms (through screening).
- Residents of the selected study region.
- Part of the population enrolled and validated in the pilot primary health care facilities.
You may not qualify if:
- Suicidal risk requiring immediate or urgent referral to care services.
- Suffering from severe psychiatric disorders or substance use disorders.
- Being in situations of declared risk that require protection (e.g., domestic violence).
- Moderate or severe disability.
- Incapacitating medical illnesses.
- Receiving other mental health treatments that could lead to over-intervention.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Chilelead
- Pan American Health Organizationcollaborator
Study Sites (1)
CESFAM Las Ánimas
Valdivia, Chile
Related Publications (2)
Schafer SK, Thomas LM, Lindner S, Lieb K. World Health Organization's low-intensity psychosocial interventions: a systematic review and meta-analysis of the effects of Problem Management Plus and Step-by-Step. World Psychiatry. 2023 Oct;22(3):449-462. doi: 10.1002/wps.21129.
PMID: 37713578RESULTAkhtar A, Koyiet P, Rahman A, Schafer A, Hamdani SU, Cuijpers P, Sijbrandij M, Bryant RA. Residual posttraumatic stress disorder symptoms after provision of brief behavioral intervention in low- and middle-income countries: An individual-patient data meta-analysis. Depress Anxiety. 2022 Jan;39(1):71-82. doi: 10.1002/da.23221. Epub 2021 Nov 9.
PMID: 34752690RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Camila A. Solís, MSc.
University of Chile
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 24, 2025
First Posted
May 23, 2025
Study Start
May 9, 2025
Primary Completion
September 12, 2025
Study Completion
October 12, 2025
Last Updated
November 20, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share
Individual Participant Data (IPD) will only be shared when required by regulatory institutions. In order to protect privacy and ensure the confidentiality of information, all data shared with research staff members without direct access to the case file will identify participants solely by their enrollment number and will be transmitted using depersonalized forms, such as the CRF. In the case it becomes necessary to share IPD with regulatory institutions, such as ethics committees or governmental agencies, the depersonalized enrollment number will be used to maintain the confidentiality of personal information. Personal information will only be shared with public health care services or as required under Chilean legislation.